The Impact of Histological Types on the Efficacy of Angiogenesis Inhibitors in the Treatment of Advanced NSCLC: A Meta-Analysis of Randomized Controlled TrialsOctober 15, 2015
This research assesses the overall efficacy of angiogenesis inhibitor (AI)-containing regimens in the treatment of advanced non-small-cell lung cancer (NSCLC).
Scientists believe that targeting blood vessel cells known as pericytes may offer a potential new therapeutic approach for breast and other cancers.
A novel DNA vaccine is being employed to kill cancer, not by attacking tumor cells, but by targeting the blood vessels that keep them alive.
This fact sheet reviews the use of angiogenesis inhibitors to prevent the formation of new blood vessels, in order to stop or slow the growth or spread of cancerous tumors.
Computerized tomography adds to lactate dehydrogenase (LDH) levels in predicting survival among persons with metastatic melanoma on bevacizumab.
News from the FDA on bosutinib (Bosulif), ziv-aflibercept (Zaltrap), and everolimus oral suspension tablets (Afinitor Disperz).
Thiabendazole, an antifungal drug in clinical use for 40 years, inhibits angiogenesis, slows tumor growth, and reduces vascular density of tumors.
New research is showing that sequence and timing have significant impact on the efficacy of therapeutic regimens that include bevacizumab.
A newly identified subtype of ovarian cancer that builds its own blood vessels may be vulnerable to agents that block blood vessel formation.
The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
The use of bevacizumab (Avastin) improved progression-free survival in women with ovarian cancer, particularly those at high risk for disease progression.
The FDA has revoked its approval of the breast cancer indication for Avastin (bevacizumab). The anti-angiogenic therapy remains indicated for some colorectal, lung, brain, and kidney cancers.
Using bevacizumab in combination with chemotherapy or biological therapy raises the risk of treatment-related death—but the agent's potential benefits may outweigh the relatively low absolute risk.
A naturally occurring protein inhibits tumor growth and metastasis into secondary organs and has the potential to be developed into an anticancer drug, scientists have found.
Doctors who monitor and help control a patient's blood pressure can minimize the side effects of novel cancer drugs, according to a paper published in the Journal of the National Cancer Institute (2010 May 5;102(9):596-604).
Targeting tumor vasculature by inhibiting angiogenesis is a promising approach for women with advanced ovarian cancer, and clinical trials should designed to ensure that novel agents are evaluated rapidly
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Encorafenib, Binimetinib Combination Receives FDA Approval for Mutation-Positive Melanoma
- Certain Risk Factors May Decrease Overall Survival in Pediatric B-NHL
- Oral Contraceptive Use May Not Be Associated With Increased Melanoma Risk
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|